Skip to main content

About Us

Pharming is a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs.

Our Strengths

Our key strengths include the following:

  • Sales growth of RUCONEST®.

  • Proven rare-disease commercialization capabilities.

  • Internal pipeline of product candidates.

  • Transgenic Production Platform Technology.

  • Data exclusivity, know-how and intellectual property.

Our Strategy

Our goal is to be a leading biopharmaceutical company focused on offering treatment options for patients with unmet medical needs, focused on rare diseases.

Our three-pillar strategy for achieving our goal is:

  • Continuing to grow sales of RUCONEST® through further country launches and increasing acute HAE attack treatment market share

  • Expanding indications for rhC1INH and clinical development and commercialization of new recombinant human proteins using our platform technology

    • rhC1INH for additional large unmet indications, such as Acute Kidney Injury, Pre-eclampsia, and COVID-19.

    • Developing more convenient forms of RUCONEST®.

    • Leveraging our transgenic manufacturing technology to develop next-generation protein replacement therapies.

  • In-licensing or acquiring drug candidates that are in the late-stages of clinical development and that can potentially leverage our commercial infrastructure

    • Developing leniolisib for the treatment of APDS.

    • Developing or acquiring new programs or companies that can be commercialized using our sales and marketing infrastructure.

Cookies: This website uses cookies Check the cookies page for more information Accept Decline